Globus Medical
NYSE: GMED · HEALTHCARE · MEDICAL DEVICES
Updated 2026-06-05
Globus Medical (GMED) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $254.34M | $288.19M | $331.48M | $385.99M | $434.46M | $474.37M | $544.75M | $563.99M | $635.98M | $712.97M | $785.37M | $789.04M | $958.10M | $1.02B | $1.57B | $2.52B | $2.94B |
| Revenue growth (YoY) | — | +13.3% | +15.0% | +16.4% | +12.6% | +9.2% | +14.8% | +3.5% | +12.8% | +12.1% | +10.2% | +0.5% | +21.4% | +6.8% | +53.3% | +60.6% | +16.7% |
| Cost of revenue | $41.61M | $53.83M | $68.80M | $75.20M | $100.34M | $110.77M | $132.33M | $134.71M | $150.45M | $159.41M | $179.97M | $217.46M | $239.22M | $263.73M | $548.17M | $1.04B | $957.80M |
| Gross profit | $212.74M | $234.37M | $262.68M | $310.80M | $334.12M | $363.60M | $412.42M | $429.29M | $485.52M | $553.56M | $605.39M | $571.58M | $718.88M | $759.12M | $1.02B | $1.48B | $1.98B |
| Gross margin | 83.6% | 81.3% | 79.2% | 80.5% | 76.9% | 76.6% | 75.7% | 76.1% | 76.3% | 77.6% | 77.1% | 72.4% | 75.0% | 74.2% | 65.1% | 58.9% | 67.4% |
| R&D | $20.52M | $21.31M | $23.46M | $27.93M | $26.87M | $31.17M | $36.31M | $44.53M | $43.68M | $55.50M | $60.07M | $84.52M | $97.35M | $73.02M | $124.01M | $163.75M | $185.00M |
| SG&A | — | $143.90M | $163.93M | $168.86M | $182.52M | $187.80M | $214.01M | $222.16M | $267.82M | $311.59M | $354.76M | $354.76M | $408.15M | $432.12M | $643.41M | $981.05M | $1.18B |
| Operating income | $81.91M | $87.69M | $97.36M | $114.79M | $101.67M | $138.36M | $172.22M | $154.14M | $161.84M | $169.32M | $171.99M | $111.43M | $171.95M | $227.95M | $133.14M | $165.99M | $479.80M |
| Operating margin | 32.2% | 30.4% | 29.4% | 29.7% | 23.4% | 29.2% | 31.6% | 27.3% | 25.4% | 23.7% | 21.9% | 14.1% | 17.9% | 22.3% | 8.5% | 6.6% | 16.3% |
| EBITDA | $97.30M | $105.67M | $115.78M | $132.68M | $120.93M | $159.59M | $195.59M | $192.99M | $205.39M | $218.51M | $229.49M | $178.35M | $264.73M | $304.50M | $346.58M | $473.73M | $729.90M |
| EBITDA margin | 38.3% | 36.7% | 34.9% | 34.4% | 27.8% | 33.6% | 35.9% | 34.2% | 32.3% | 30.6% | 29.2% | 22.6% | 27.6% | 29.8% | 22.1% | 18.8% | 24.8% |
| EBIT | $83.79M | $90.47M | $98.83M | $114.57M | $101.53M | $137.84M | $171.50M | $154.22M | $163.32M | $176.88M | $176.75M | $115.47M | $194.86M | $236.25M | $201.85M | $219.70M | $609.90M |
| Interest expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $805000.00 | $1.30M | $3.06M | $6.61M | $13.28M | $17.41M | $13.95M | $9.30M | $14.23M | $20.13M | $4.19M | — |
| Income tax | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $48.73M | $54.46M | $60.78M | $73.83M | $68.61M | $92.48M | $112.78M | $104.34M | $107.35M | $156.47M | $155.21M | $102.28M | $149.19M | $190.17M | $122.87M | $102.98M | $537.90M |
| Net income growth (YoY) | — | +11.7% | +11.6% | +21.5% | -7.1% | +34.8% | +21.9% | -7.5% | +2.9% | +45.8% | -0.8% | -34.1% | +45.9% | +27.5% | -35.4% | -16.2% | +422.3% |
| Profit margin | 19.2% | 18.9% | 18.3% | 19.1% | 15.8% | 19.5% | 20.7% | 18.5% | 16.9% | 21.9% | 19.8% | 13.0% | 15.6% | 18.6% | 7.8% | 4.1% | 18.3% |
Frequently asked questions
What is Globus Medical's revenue?
Globus Medical's trailing twelve-month revenue is $3.10B. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.
How profitable is GMED?
In its most recent fiscal year, GMED ran a gross margin of 67.41%, an operating margin of 16.33%, and a net margin of 18.30%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.
How much free cash flow does GMED generate?
GMED produced $588.77M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is GMED's balance sheet healthy?
GMED holds $526.16M in cash and equivalents against — in long-term debt, on $4.57B of shareholder equity. That debt is best read against the cash flow the business throws off each year.